Clinical And Economic Benefit Of Upper Airway Stimulation For Obstructive Sleep Apnea In The German Setting

Abstract

0 1 7 ) A 3 9 9 -A 8 1 1 A581 0.34, respectively) and increased survival by 1.27 life years. While the UAS strategy incurred an additional 1.02 QALYs, there were also additional mean costs of 54,578 Euros over the patient's lifetime, resulting in an incremental cost-effectiveness ratio of € 53,698 per QALY gained. ConClusions: Upper airway stimulation adds meaningful benefit to endpoints relevant to obstructive sleep apnea patients and is a cost-effective therapy for patients ineligible to continuous positive pressure ventilation in the German healthcare setting. PMD52